News
Public · Published
DataMeds AI LOI Maps Out Asset Acquisitions and Licenses for 89.5% Stake Allocation
DataMeds AI signed a non-binding amended letter of intent with EOS, Scilex, Datavault, HBA, THI and REBOOT. The deal combines intellectual property acquisitions and licenses with a controlling stake in HLH, with named recipients and Fortitude expected to own about 89.5% of DataMeds AI after closing.
Published:
Updated:
What happened
DataMeds AI signed a non-binding amended letter of intent with EOS, Scilex, Datavault, HBA, THI and REBOOT. The deal combines intellectual property acquisitions and licenses with a controlling stake in HLH, with named recipients and Fortitude expected to own about 89.5% of DataMeds AI after closing.
Confirmed
Global impact / market context
Existing DataMeds AI holders would see their ownership fall sharply if the deal closes, because the named recipients and Fortitude would together hold about 89.5% of the company. That would leave current investors with a much smaller share of future profits and voting power, which means control of the company would shift.
Analyst inference
The deal is only a non-binding letter of intent, so it may never close. Completion depends on definitive agreements, required approvals, and total liabilities of no more than $2 million. REBOOT's portion may close separately or not at all, so the final ownership split could differ from the 89.5% figure.
Analyst inference
What to watch
- Exclusivity runs through Nov 30 2026, and definitive agreements and closing are still pending, so watch whether binding contracts are actually signed before that exclusivity period ends. Confirmed
- Watch whether the parties agree to royalties and governance changes outlined in the letter of intent, since these terms would shape future cash flows and who controls DataMeds AI. Proposed
- Watch the $2 million liability threshold, because exceeding it could block closing. Track REBOOT's separate transaction, since its outcome could change the final ownership split. Analyst inference
Evidence
- Original source link unavailable